Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia.
Twenty-two patients with newly diagnosed acute myelocytic leukemia (AML) and white cell counts (WBC) greater than 100,000/microliters received one, two, or three leukaphereses prior to induction chemotherapy with cytosine arabinoside (Ara-C) and daunorubicin (DNR). Fifteen of 22 (68%) achieved a complete remission. Greater than a 30% decrease in initial WBC was found to be an important predictor of response. Fifteen of 17 patients (88%) with greater than 30% reduction of initial WBC achieved remission, while none of 5 patients with less than a 30% reduction responded (P = 0.001).
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007937:Leukapheresis; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D007958:Leukocyte Count; D007964:Leukocytosis / Q000150:complications* / Q000628:therapy; D008875:Middle Aged
D003561:Cytarabine; D003630:Daunorubicin